NASDAQ:HSDT - Helius Medical Technologies Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $20.00
  • Forecasted Upside: 50.94 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$13.25
+0.30 (1.20%)

This chart shows the closing price for HSDT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Helius Medical Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HSDT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HSDT

Analyst Price Target is $20.00
▲ +50.94% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Helius Medical Technologies in the last 3 months. The average price target is $20.00, with a high forecast of $20.00 and a low forecast of $20.00. The average price target represents a 50.94% upside from the last price of $13.25.

This chart shows the closing price for HSDT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Helius Medical Technologies. This rating has held steady since January 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/26/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/25/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/16/2021Noble FinancialReiterated RatingBuy$20.00Low
3/24/2021Noble FinancialInitiated CoverageOutperform$20.00Medium
2/12/2021LADENBURG THALM/SH SHInitiated CoverageBuyLow
8/12/2020OppenheimerReiterated RatingHoldHigh
5/12/2020OppenheimerInitiated CoverageHoldHigh
8/9/2019BTIG ResearchReiterated RatingHoldN/A
4/16/2019BTIG ResearchDowngradeBuy ➝ NeutralHigh
4/10/2019OppenheimerDowngradeOutperform ➝ HoldHigh
3/18/2019BTIG ResearchReiterated RatingBuyHigh
3/5/2019OppenheimerInitiated CoverageBuy$350.00High
1/27/2019BTIG ResearchReiterated RatingBuy$490.00Low
11/20/2018BTIG ResearchUpgradeNeutral ➝ Buy$490.00Medium
6/19/2018BTIG ResearchReiterated RatingBuy ➝ Neutral$490.00High
5/17/2018BTIG ResearchInitiated CoverageBuy$490.00Low
(Data available from 10/23/2016 forward)

News Sentiment Rating

0.87 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/26/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/25/2021
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/25/2021
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/24/2021
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/23/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/23/2021

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Helius Medical Technologies logo
Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain's ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational Portable Neuromodulation Stimulator (PoNS), that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA.
Read More

Today's Range

Now: $13.25
Low: $13.17
High: $13.53

50 Day Range

MA: $14.34
Low: $12.90
High: $15.39

52 Week Range

Now: $13.25
Low: $11.00
High: $34.00

Volume

2,432 shs

Average Volume

59,562 shs

Market Capitalization

$30.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Frequently Asked Questions

What sell-side analysts currently cover shares of Helius Medical Technologies?

The following sell-side analysts have issued research reports on Helius Medical Technologies in the last twelve months: LADENBURG THALM/SH SH, Noble Financial, and Zacks Investment Research.
View the latest analyst ratings for HSDT.

What is the current price target for Helius Medical Technologies?

1 Wall Street analysts have set twelve-month price targets for Helius Medical Technologies in the last year. Their average twelve-month price target is $20.00, suggesting a possible upside of 50.9%. Noble Financial has the highest price target set, predicting HSDT will reach $20.00 in the next twelve months. Noble Financial has the lowest price target set, forecasting a price of $20.00 for Helius Medical Technologies in the next year.
View the latest price targets for HSDT.

What is the current consensus analyst rating for Helius Medical Technologies?

Helius Medical Technologies currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HSDT will outperform the market and that investors should add to their positions of Helius Medical Technologies.
View the latest ratings for HSDT.

What other companies compete with Helius Medical Technologies?

How do I contact Helius Medical Technologies' investor relations team?

Helius Medical Technologies' physical mailing address is 642 NEWTOWN YARDLEY ROAD SUITE 100, NEWTOWN PA, 18940. The company's listed phone number is (215) 944-6100 and its investor relations email address is [email protected] The official website for Helius Medical Technologies is heliusmedical.com.